ZyVersa Therapeutics Past Earnings Performance
Past criteria checks 0/6
ZyVersa Therapeutics's earnings have been declining at an average annual rate of -48.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-48.8%
Earnings growth rate
-34.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -303.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ZyVersa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -29 | 8 | 2 |
| 30 Jun 24 | 0 | -22 | 8 | 2 |
| 31 Mar 24 | 0 | -106 | 10 | 3 |
| 31 Dec 23 | 0 | -106 | 11 | 3 |
| 30 Sep 23 | 0 | -88 | 11 | 5 |
| 30 Jun 23 | 0 | -98 | 12 | 6 |
| 31 Mar 23 | 0 | -14 | 9 | 6 |
| 31 Dec 22 | 0 | -14 | 8 | 6 |
| 30 Sep 22 | 0 | -21 | 6 | 5 |
| 30 Jun 22 | 0 | -10 | 6 | 3 |
| 31 Mar 22 | 0 | -10 | 7 | 3 |
| 31 Dec 21 | 0 | -8 | 6 | 2 |
Quality Earnings: ZVSA is currently unprofitable.
Growing Profit Margin: ZVSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZVSA is unprofitable, and losses have increased over the past 5 years at a rate of 48.8% per year.
Accelerating Growth: Unable to compare ZVSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZVSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ZVSA has a negative Return on Equity (-303.53%), as it is currently unprofitable.